Breaking News Instant updates and real-time market news.

GILD

Gilead

$74.69

0.9 (1.22%)

, KITE

Acquired by GILD 9/17

$178.05

38.95 (28.00%)

07:49
08/29/17
08/29
07:49
08/29/17
07:49

Gilead price target raised to $85 from $79 at Credit Suisse

Credit Suisse analyst Alethia Young raised her price target for Gilead (GILD) to $85 from $79 after adding some Kite Pharma (KITE) platform credit over the long-term. The analyst likes the Kite acquisition and says it marks the beginning of a new chapter. Young reiterates an Outperform rating on Gilead's shares.

GILD

Gilead

$74.69

0.9 (1.22%)

KITE

Acquired by GILD 9/17

$178.05

38.95 (28.00%)

  • 29

    Aug

  • 08

    Sep

  • 11

    Sep

  • 29

    Nov

  • 12

    Feb

GILD Gilead
$74.69

0.9 (1.22%)

08/28/17
NEED
08/28/17
NO CHANGE
NEED
Buy
Gilead's long-term position in oncology unclear, says Needham
Needham analyst Alan Carr says that while the acquisition of Kite Pharma (KITE) creates an opportunity for Gilead Sciences (GILD) to become an important player in oncology, there is enough uncertainty around the technology and the competitive landscape such that it is unclear whether Gilead will emerge a long-term leader in the space. The analyst keeps a Hold rating on Gilead shares.
08/28/17
WELS
08/28/17
NO CHANGE
Target $180
WELS
Market Perform
Wells Fargo sees little chance of higher bid for Kite Pharma
The price paid by Gilead Sciences (GILD) "more than adequately" reflects potential value from Kite Pharma's (KITE) AxiCel and adoptive cellular therapy pipeline, Wells Fargo analyst Jim Birchenough tells investors in a research note. The analyst sees "little chance" of a higher offer or a price bump by Gilead. He raised his price target for Kite shares to $180 and keeps a Market Perform rating on the name. The stock in afternoon trading is just below Gilead's $180 per share takeover offer at $178.12. The shares are up 28% on the day, or $39.02.
08/29/17
ADAM
08/29/17
DOWNGRADE
Target $180
ADAM
Hold
Kite Pharma downgraded to Hold from Buy at Canaccord
Canaccord analyst John Newman downgraded Kite Pharma (KITE) to Hold from Buy after the company agreed to be acquired by Gilead (GILD) for $180 per share.
08/29/17
WEDB
08/29/17
UPGRADE
WEDB
Outperform
Juno Therapeutics upgraded on Kite deal at Wedbush
As noted earlier, Wedbush upgraded Juno (JUNO) to Outperform from Neutral. Analyst David Nierengarten,upgraded Juno following Gilead's (GILD) proposed acquisition of Kite Pharma (KITE). The analyst believes the acquisition serves as validation for the CAR-T cell therapy space and thinks the deal will enhance the awareness of and infrastructure supporting CAR-T therapies by the time Juno's JCAR017 hits the market in late 2018/early 2019. Nierengarten estimates that Juno's pipeline in hematologic malignancies will generate peak U.S. sales of $2B. Target to $42 from $24.
KITE Acquired by GILD 9/17
$178.05

38.95 (28.00%)

08/28/17
GUGG
08/28/17
DOWNGRADE
GUGG
Neutral
Kite Pharma downgraded to Neutral from Buy at Guggenheim
Kite Pharma (KITE) is being acquired by Gilead (GILD) for $180 per share.

TODAY'S FREE FLY STORIES

AWK

American Water

$97.50

-0.22 (-0.23%)

05:50
12/11/18
12/11
05:50
12/11/18
05:50
Earnings
American Water backs FY18 adj. EPS view $3.27-$3.32, consensus $3.30 »

American Water affirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TLRA

Telaria

$2.89

0.12 (4.33%)

05:49
12/11/18
12/11
05:49
12/11/18
05:49
Conference/Events
Telaria management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 17

    Dec

  • 18

    Dec

TILE

Interface

$14.96

-0.17 (-1.12%)

05:48
12/11/18
12/11
05:48
12/11/18
05:48
Conference/Events
Interface management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

WPP

WPP

$51.13

-0.98 (-1.88%)

05:47
12/11/18
12/11
05:47
12/11/18
05:47
Periodicals
WPP to cut 3,500 jobs worldwide as part of restructuring efforts, FT reports »

WPP will cut 3,500 jobs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TCBK

TriCo Bancshares

$36.22

-0.1 (-0.28%)

05:47
12/11/18
12/11
05:47
12/11/18
05:47
Conference/Events
TriCo Bancshares management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

  • 14

    Dec

SFIX

Stitch Fix

$25.92

-0.42 (-1.59%)

05:47
12/11/18
12/11
05:47
12/11/18
05:47
Downgrade
Stitch Fix rating change  »

Stitch Fix downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYX

Systemax

$30.46

4.37 (16.75%)

05:45
12/11/18
12/11
05:45
12/11/18
05:45
Conference/Events
Systemax management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

WPP

WPP

$51.13

-0.98 (-1.88%)

05:45
12/11/18
12/11
05:45
12/11/18
05:45
Hot Stocks
WPP sees medium-term organic growth in line with peers »

The company will incur…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

05:45
12/11/18
12/11
05:45
12/11/18
05:45
General news
NFIB Small Business Optimism Index level to be reported at 06:00 »

November NFIB Small…

WPP

WPP

$51.13

-0.98 (-1.88%)

05:44
12/11/18
12/11
05:44
12/11/18
05:44
Hot Stocks
WPP to incur cash costs for restructuring of GBP300M over three years »

WPP announces the results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

FB

Facebook

$141.87

4.45 (3.24%)

05:40
12/11/18
12/11
05:40
12/11/18
05:40
Periodicals
Vishal Shah named head of product for all of Instagram, Recode reports »

Vishal Shah, a product…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

, GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

05:39
12/11/18
12/11
05:39
12/11/18
05:39
Hot Stocks
YouTube bans Proud Boys founder Gavin McInnes »

The YouTube account of…

GOOG

Alphabet

$1,040.02

3.5 (0.34%)

GOOGL

Alphabet Class A

$1,052.80

5.81 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 03

    Mar

CWBR

CohBar

$3.64

0.17 (4.90%)

05:37
12/11/18
12/11
05:37
12/11/18
05:37
Conference/Events
CohBar to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

WMT

Walmart

$93.92

0.71 (0.76%)

05:36
12/11/18
12/11
05:36
12/11/18
05:36
Hot Stocks
Walmart, Rakuten open first Walmart ecommerce store in Japan »

Rakuten, Inc. and Walmart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNFT

Benefitfocus

$50.82

(0.00%)

05:30
12/11/18
12/11
05:30
12/11/18
05:30
Recommendations
Benefitfocus analyst commentary  »

Benefitfocus price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

VRNT

Verint

$44.86

-0.23 (-0.51%)

05:25
12/11/18
12/11
05:25
12/11/18
05:25
Recommendations
Verint analyst commentary  »

Verint price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

NCSM

NCS Multistage

$6.84

-0.37 (-5.13%)

05:22
12/11/18
12/11
05:22
12/11/18
05:22
Downgrade
NCS Multistage rating change  »

NCS Multistage downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCJY

SLC Agricola

$0.00

(0.00%)

05:20
12/11/18
12/11
05:20
12/11/18
05:20
Upgrade
SLC Agricola rating change  »

SLC Agricola upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$44.41

0.49 (1.12%)

05:18
12/11/18
12/11
05:18
12/11/18
05:18
Downgrade
Pfizer rating change  »

Pfizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Dec

IKTSY

Intertek

$0.00

(0.00%)

05:13
12/11/18
12/11
05:13
12/11/18
05:13
Upgrade
Intertek rating change  »

Intertek upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$152.58

-0.875 (-0.57%)

05:07
12/11/18
12/11
05:07
12/11/18
05:07
Downgrade
Wex rating change  »

Wex downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

FLT

FleetCor

$186.15

-0.78 (-0.42%)

05:06
12/11/18
12/11
05:06
12/11/18
05:06
Downgrade
FleetCor rating change  »

FleetCor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

FIS

FIS

$105.72

1.07 (1.02%)

05:05
12/11/18
12/11
05:05
12/11/18
05:05
Upgrade
FIS rating change  »

FIS upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

FISV

Fiserv

$76.15

1.42 (1.90%)

05:05
12/11/18
12/11
05:05
12/11/18
05:05
Upgrade
Fiserv rating change  »

Fiserv upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACOR

Acorda Therapeutics

$19.08

0.48 (2.58%)

05:03
12/11/18
12/11
05:03
12/11/18
05:03
Downgrade
Acorda Therapeutics rating change  »

Acorda Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.